Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Epizyme, Inc.EPZM · Entity 12703 | Chief Financial Officer | February 04, 2021 | February 05, 2021 |
| INSMED IncINSM · Entity 3174 | Chief Financial Officer | January 03, 2019 | January 07, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Epizyme, Inc.
Report date February 04, 2021 · Filed February 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 53,465 |
Reported balance
After 2021-02-04 transaction · row 1
1 source rowRow 1 · 2021-02-04 · Sale · Disposed 1,021 · Balance 53,465 F1: Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the restricted stock units granted under the issuer's 2013 Stock Incentive Plan on February 3, 2020. The automatic sale of the reporting person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the restricted stock units granted under the issuer's 2013 Stock Incentive Plan on February 3, 2020. The automatic sale of the reporting person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person.
INSMED Inc
Report date January 03, 2019 · Filed January 07, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $13.91 · Expires 2029-01-03 | Direct | 120,280 |
Reported balance
After 2019-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-03 · Grant · Acquired 120,280 · Balance 120,280 F1: Stock options granted under the Company's 2017 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty-five percent (25%) on the first anniversary of the grant date and an additional twelve and one-half percent (12.5%) vest on the six month anniversary of the first anniversary date and each six month anniversary date thereafter through the fourth anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options granted under the Company's 2017 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty-five percent (25%) on the first anniversary of the grant date and an additional twelve and one-half percent (12.5%) vest on the six month anniversary of the first anniversary date and each six month anniversary date thereafter through the fourth anniversary of the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Turning Point Therapeutics, Inc.
Report date August 17, 2022 · Filed August 17, 2022
Section 16 reporting ended · disclosed 2022-08-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 1
1 source rowRow 1 · 2022-08-17 · Disposition to issuer · Disposed 29,778 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for $76.00 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Cash Amount. F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding restricted stock unit award ("RSU") whether vested or unvested was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to $76.00 per Share issuable in settlement of such RSU immediately before the effective time of the Merger, net of any withholding taxes required to be deducted and withheld by applicable law. F3: Includes 1,078 shares acquired on June 10, 2022 pursuant to the Issuer's Employee Stock Purchase Plan. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $62.63 · Expires 2031-07-25 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-17 · Disposition to issuer · Disposed 61,200 · Balance 0 F4: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.68 · Expires 2032-02-08 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-17 · Disposition to issuer · Disposed 58,600 · Balance 0 F4: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for $76.00 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Cash Amount.
F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding restricted stock unit award ("RSU") whether vested or unvested was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to $76.00 per Share issuable in settlement of such RSU immediately before the effective time of the Merger, net of any withholding taxes required to be deducted and withheld by applicable law.
F3: Includes 1,078 shares acquired on June 10, 2022 pursuant to the Issuer's Employee Stock Purchase Plan.
F4: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2022 Filed Aug 17, 2022 16:31 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Disposition to issuerStock Option (right to buy) · Derivative | 58,600 | Not disclosed Strike: $37.68 | Not disclosed |
DisclosureSEC source: 0001209191-22-046272 · doc4.xml · derivative · entry 3 TOMBESI PAOLO · CIK 0001707648 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 58,600 shares Expires 2032-02-08 F4 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. F4 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. Read SEC document |
| August 17, 2022 Filed Aug 17, 2022 16:31 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Disposition to issuerStock Option (right to buy) · Derivative | 61,200 | Not disclosed Strike: $62.63 | Not disclosed |
DisclosureSEC source: 0001209191-22-046272 · doc4.xml · derivative · entry 2 TOMBESI PAOLO · CIK 0001707648 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 61,200 shares Expires 2031-07-25 F4 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. F4 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. Read SEC document |
| August 17, 2022 Filed Aug 17, 2022 16:31 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Disposition to issuerCommon Stock | 29,778 | $76.00 | $2,263,128.00 |
DisclosureSEC source: 0001209191-22-046272 · doc4.xml · nonDerivative · entry 1 TOMBESI PAOLO · CIK 0001707648 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for $76.00 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Cash Amount. F2 · shares: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding restricted stock unit award ("RSU") whether vested or unvested was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to $76.00 per Share issuable in settlement of such RSU immediately before the effective time of the Merger, net of any withholding taxes required to be deducted and withheld by applicable law. F3 · shares: Includes 1,078 shares acquired on June 10, 2022 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| July 27, 2022 Filed Jul 29, 2022 16:18 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,183 | $74.94 | $88,654.02 |
DisclosureSEC source: 0001209191-22-043510 · doc4.xml · nonDerivative · entry 1 TOMBESI PAOLO · CIK 0001707648 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,700 F1 · kind: Sale of shares of common stock to cover tax withholding obligations associated with the vesting of a restricted stock unit award granted to Reporting Person on July 26, 2021. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 18:11 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GrantStock Option (right to buy) · Derivative | 58,600 | $0.00 Strike: $37.68 | $0.00 |
DisclosureSEC source: 0001209191-22-008985 · doc4.xml · derivative · entry 2 TOMBESI PAOLO · CIK 0001707648 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,600 Underlying: Common Stock · 58,600 shares Expires 2032-02-08 F2 · derivative.exercise_date: 1/48th of the shares vest monthly following February 9, 2022. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 18:11 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GrantCommon Stock | 16,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008985 · doc4.xml · nonDerivative · entry 1 TOMBESI PAOLO · CIK 0001707648 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,883 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2019 Equity Plan. Read SEC document |
| July 26, 2021 Filed Jul 27, 2021 18:22 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GrantStock Option (right to buy) · Derivative | 61,200 | $0.00 Strike: $62.63 | $0.00 |
DisclosureSEC source: 0001209191-21-048337 · doc4.xml · derivative · entry 2 TOMBESI PAOLO · CIK 0001707648 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,200 Underlying: Common Stock · 61,200 shares Expires 2031-07-25 F2 · derivative.exercise_date: 25% of the shares vest on July 26, 2022 and 1/48th of the shares vest monthly thereafter over the next three years. Read SEC document |
| July 26, 2021 Filed Jul 27, 2021 18:22 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GrantCommon Stock | 13,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-048337 · doc4.xml · nonDerivative · entry 1 TOMBESI PAOLO · CIK 0001707648 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,600 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2019 Equity Incentive Plan. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 16:40 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommon Stock, par value $0.0001 | 1,021 | $11.21 | $11,445.41 |
DisclosureSEC source: 0000899243-21-005042 · doc4.xml · nonDerivative · entry 1 TOMBESI PAOLO · CIK 0001707648 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,465 F1 · shares: Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the restricted stock units granted under the issuer's 2013 Stock Incentive Plan on February 3, 2020. The automatic sale of the reporting person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 21:07 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantStock Option (Right to Buy) · Derivative | 124,239 | $0.00 Strike: $11.02 | $0.00 |
DisclosureSEC source: 0000899243-21-004516 · doc4.xml · derivative · entry 2 TOMBESI PAOLO · CIK 0001707648 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,239 Underlying: Common Stock · 124,239 shares Expires 2031-01-31 F4 · derivative.exercise_date: This option was granted on February 1, 2021 pursuant to the Company's 2013 Stock Incentive Plan with respect to 124,239 shares of Common Stock, with 25% vesting on February 1, 2022 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 21:07 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon Stock | 26,041 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004516 · doc4.xml · nonDerivative · entry 1 TOMBESI PAOLO · CIK 0001707648 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,486 F1 · shares: Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in four equal annual installments over four years from the grant date, with the first installment vesting on February 1, 2022. F2 · balance_after: The reporting person acquired 996 shares of Common Stock under the Issuer's 2013 Employee Stock Purchase Plan (the "2013 ESPP") on February 29, 2020 that were not previously reported on Form 4. F3 · balance_after: The reporting person acquired 543 shares of Common Stock under the 2013 ESPP on August 31, 2020. Read SEC document |
| August 20, 2020 Filed Aug 21, 2020 16:15 UTC | Epizyme, Inc. EPZM · Entity 12703 | Tax withholdingCommon Stock, par value $0.0001 | 2,091 | $12.55 | $26,242.05 |
DisclosureSEC source: 0000899243-20-023197 · doc4.xml · nonDerivative · entry 2 TOMBESI PAOLO · CIK 0001707648 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,906 Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 16:15 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionRestricted Stock Units · Derivative | 7,055 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-023197 · doc4.xml · derivative · entry 3 TOMBESI PAOLO · CIK 0001707648 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,162 Underlying: Common Stock · 7,055 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On August 19, 2019, the reporting person was granted 28,217 restricted stock units, vesting in four equal annual installments beginning August 19, 2020. F2 · derivative.expiration_date: On August 19, 2019, the reporting person was granted 28,217 restricted stock units, vesting in four equal annual installments beginning August 19, 2020. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 16:15 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommon Stock, par value $0.0001 | 7,055 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-023197 · doc4.xml · nonDerivative · entry 1 TOMBESI PAOLO · CIK 0001707648 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 08:57 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommon Stock, par value $0.0001 | 1,805 | $16.15 | $29,150.75 |
DisclosureSEC source: 0000899243-20-017902 · doc4.xml · nonDerivative · entry 2 TOMBESI PAOLO · CIK 0001707648 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,942 F2 · shares: Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the restricted stock units described in footnote 1. The automatic sale of the reporting person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person. Read SEC document |
| June 25, 2020 Filed Jun 30, 2020 08:57 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon Stock, par value $0.0001 | 6,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-017902 · doc4.xml · nonDerivative · entry 1 TOMBESI PAOLO · CIK 0001707648 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,747 F1 · price: Represents common stock issued upon vesting of restricted stock units granted under the issuer's 2013 Stock Incentive Plan that vested upon the issuer's achievement of a specified performance target. The transaction date represents the date on which the issuer's Compensation Committee determined that the performance target was achieved. Read SEC document |
| March 25, 2020 Filed Mar 26, 2020 21:01 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommon Stock, par value $0.0001 | 1,243 | $15.28 | $18,993.04 |
DisclosureSEC source: 0000899243-20-009607 · doc4.xml · nonDerivative · entry 2 TOMBESI PAOLO · CIK 0001707648 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,437 F2 · shares: Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the restricted stock units described in footnote 1. The automatic sale of the reporting person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person. Read SEC document |
| March 24, 2020 Filed Mar 26, 2020 21:01 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon Stock, par value $0.0001 | 1,690 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-009607 · doc4.xml · nonDerivative · entry 1 TOMBESI PAOLO · CIK 0001707648 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,680 F1 · price: Represents common stock issued upon vesting of restricted stock units granted under the issuer's 2013 Stock Incentive Plan that vested upon the issuer's achievement of a specified performance target. The transaction date represents the date on which the issuer's Compensation Committee determined that the performance target was achieved. Read SEC document |
| March 24, 2020 Filed Jun 30, 2020 06:06 UTC Amendment | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon Stock, par value $0.0001 | 4,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-017854 · doc4a.xml · nonDerivative · entry 1 TOMBESI PAOLO · CIK 0001707648 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,747 F1 · shares: The Form 4 originally filed on March 26, 2020 inadvertently reported an incorrect amount of shares of common stock issued to the reporting person upon vesting of restricted stock units granted under the issuer's 2013 Stock Incentive Plan. F1 · price: The Form 4 originally filed on March 26, 2020 inadvertently reported an incorrect amount of shares of common stock issued to the reporting person upon vesting of restricted stock units granted under the issuer's 2013 Stock Incentive Plan. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 18:00 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantStock Option (Right to Buy) · Derivative | 56,213 | $0.00 Strike: $21.39 | $0.00 |
DisclosureSEC source: 0000899243-20-003366 · doc4.xml · derivative · entry 2 TOMBESI PAOLO · CIK 0001707648 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,213 Underlying: Common Stock · 56,213 shares Expires 2030-02-02 F2 · derivative.exercise_date: This option was granted on February 3, 2020 pursuant to the Company's 2013 Stock Incentive Plan with respect to 56,213 shares of Common Stock, with 25% vesting on February 3, 2021 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 18:00 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon Stock | 11,688 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-003366 · doc4.xml · nonDerivative · entry 1 TOMBESI PAOLO · CIK 0001707648 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,990 F1 · shares: Consists of shares of Common Stock issuable under 11,688 restricted stock units ("RSUs") granted pursuant to the Company's 2013 Stock Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in four equal annual installments over four years from the grant date, with the first installment vesting on February 3, 2021. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 21:15 UTC | Epizyme, Inc. EPZM · Entity 12703 | Tax withholdingCommon Stock, par value $0.0001 | 1,698 | $26.72 | $45,370.56 |
DisclosureSEC source: 0000899243-20-002109 · doc4.xml · nonDerivative · entry 2 TOMBESI PAOLO · CIK 0001707648 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,302 Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 21:15 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon Stock, par value $0.0001 | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-002109 · doc4.xml · nonDerivative · entry 1 TOMBESI PAOLO · CIK 0001707648 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · price: Represents common stock issued upon vesting of restricted stock units granted under the issuer's 2013 Stock Incentive Plan that vested upon the issuer's achievement of a specified performance target. The transaction date represents the date on which the issuer's Compensation Committee determined that the performance target was achieved. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 06:06 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantRestricted Stock Units · Derivative | 28,217 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-022189 · doc4.xml · derivative · entry 2 TOMBESI PAOLO · CIK 0001707648 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,217 Underlying: Common Stock · 28,217 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. F3 · derivative.exercise_date: This award, granted on August 19, 2019, pursuant to the Company's 2013 Stock Incentive Plan, vests in four equal annual installments beginning August 19, 2020. Vested shares will be delivered to the reporting person. F3 · derivative.expiration_date: This award, granted on August 19, 2019, pursuant to the Company's 2013 Stock Incentive Plan, vests in four equal annual installments beginning August 19, 2020. Vested shares will be delivered to the reporting person. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 06:06 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantStock Option (Right to Buy) · Derivative | 132,225 | $0.00 Strike: $13.86 | $0.00 |
DisclosureSEC source: 0000899243-19-022189 · doc4.xml · derivative · entry 1 TOMBESI PAOLO · CIK 0001707648 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,225 Underlying: Common Stock · 132,225 shares Expires 2029-08-18 F1 · derivative.exercise_date: This option was granted on August 19, 2019 pursuant to the Company's 2013 Stock Incentive Plan with respect to 132,225 shares of Epizyme, Inc. common stock, with 25% vesting on August 19, 2020 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 21:08 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option · Derivative | 120,280 | $0.00 Strike: $13.91 | $0.00 |
DisclosureSEC source: 0001127430-19-000018 · edgar.xml · derivative · entry 1 TOMBESI PAOLO · CIK 0001707648 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,280 Underlying: Common Stock · 120,280 shares Expires 2029-01-03 F1 · derivative.exercise_date: Stock options granted under the Company's 2017 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty-five percent (25%) on the first anniversary of the grant date and an additional twelve and one-half percent (12.5%) vest on the six month anniversary of the first anniversary date and each six month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 21:11 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option · Derivative | 55,400 | $0.00 Strike: $30.46 | $0.00 |
DisclosureSEC source: 0001127430-18-000021 · edgar.xml · derivative · entry 2 TOMBESI PAOLO · CIK 0001707648 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,400 Underlying: Common Stock · 55,400 shares Expires 2028-01-04 F3 · derivative.exercise_date: Stock options granted under the Company's 2017 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty-five percent (25%) on the first anniversary of the grant date and an additional twelve and one-half percent (12.5%) vest on the six month anniversary of the first anniversary date and each six month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 21:11 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 10,669 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127430-18-000021 · edgar.xml · nonDerivative · entry 1 TOMBESI PAOLO · CIK 0001707648 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,669 F1 · shares: Restricted stock units granted pursuant to the Company's 2017 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the grant. F2 · price: Each Restricted Stock Unit was received as a grant on January 4, 2018, for no consideration, and represents a contingent right to receive one share of Common Stock. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:09 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option · Derivative | 127,160 | $0.00 Strike: $15.60 | $0.00 |
DisclosureSEC source: 0001127430-17-000065 · edgar.xml · derivative · entry 1 TOMBESI PAOLO · CIK 0001707648 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,160 Underlying: Common Stock · 127,160 shares Expires 2027-06-01 F1 · derivative.exercise_date: In connection with the appointment of Mr. Tombesi as the Company's Chief Financial Officer, the Company granted Mr. Tombesi an option to purchase a total of 127,160 shares of the Company's common stock. The option becomes exercisable based on the following vesting schedule: twenty-five percent (25%) vest on the first anniversary of the date of grant and twelve and one-half percent (12.5%) vest on each six month anniversary date through the fourth anniversary of the date of grant, subject to Mr. Tombesi's continued employment with the Company on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.